Xeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability.
The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post Xeris Pharmaceuticals touts data for glucagon auto-injector appeared first on MassDevice.
from MassDevice https://ift.tt/2DDQDCv
Cap comentari:
Publica un comentari a l'entrada